Antibody-drug Conjugate Information
General Information of This Antibody-drug Conjugate (ADC)
| ADC ID |
DRG0WGZXJ
|
|||||
|---|---|---|---|---|---|---|
| ADC Name |
F8-TNF
|
|||||
| Synonyms |
F8 TNF
Click to Show/Hide
|
|||||
| Drug Status |
Investigative
|
|||||
| Antibody Name |
scFv(F8) Anti-ody
|
Antibody Info | ||||
| Antigen Name |
T-cell surface glycoprotein CD8 alpha chain (CD8A); T-cell surface glycoprotein CD8 alpha chain (CD8A)
|
Antigen Info | ||||
| Payload Name |
Undisclosed
|
|||||
| Therapeutic Target |
Stimulator of interferon genes protein (STING1)
|
Target Info | ||||
| Linker Name |
Undisclosed
|
|||||
General Information of The Activity Data Related to This ADC
Full List of Activity Data of This Antibody-drug Conjugate
Discovered Using Cell Line-derived Xenograft Model
| Experiment 1 Reporting the Activity Date of This ADC | [1] | ||||
| Efficacy Data | Tumor Growth Inhibition value (TGI) | ≈ 86.70% | Moderate CD8 expression (CD8 ++) | ||
| Method Description |
CT26 Cells were implanted subcutaneously (s.c.) in the right flank of the mice using 3x106 cells per animal. Mice received three injections of either 1 g F8-TNF (WEHI-164 tumor-bearing mice) or 2.5 g (CT26 tumor-bearing mice) every 48 h starting on the day after vaccination.
|
||||
| In Vivo Model | CT26 CDX model | ||||
| In Vitro Model | Colon carcinoma | CT26 cells | CVCL_7254 | ||
References